PROGRAM CHAIR/HOST
Eric Kumar Singhi, MD
Assistant Professor
The University of Texas MD Anderson Cancer Center
Houston, Texas
Podcast Guest Faculty
Bruna Pellini, MD
Chief of Thoracic Medical Oncology
Miami Cancer Institute
Baptist Health South Florida
Miami, Florida
OVERVIEW
This engaging Podcast Series explores different facets of integrating advances in identifying and treating HER2-mutant NSCLC. In the first of three podcasts, expert faculty discuss the distinct HER2 pathologic alterations identified in NSCLC patients including their prevalence and associated clinical characteristics. The second podcast examines the importance of comprehensive molecular profiling to improve outcomes in HER2-altered NSCLC including challenges faced in integrating diagnostic testing in the community setting. The final podcast in the series evaluates treatment sequencing strategies for advanced HER2-mutant NSCLC including new approvals for HER2-directed tyrosine kinase inhibitors as well as patient-specific factors that guide incorporation of these targeted treatments in first-line and beyond lines of therapy to improve efficacy and safety.
TARGET AUDIENCE
This activity is designed to meet the educational needs of community clinicians involved in the evaluation and management of patients with lung cancer including oncologists, nurses/nurse practitioners, and physician assistants.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Describe the human epidermal growth factor receptor 2 (HER2) alterations in HER2-mutant non-small cell lung cancer (NSCLC) as well as the prevalence, patient population, and burden of disease
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this virtual activity for a maximum of 0.25 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the virtual activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.25 ANCC contact hours.
ACCME INNOVATION PARTNER
Med Learning Group (MLG) is proud to be recognized as an ACCME Innovation Partner, leading the way in simplifying CME for physicians. As an Innovation Partner, MLG will be working with the ACCME by submitting credits directly to CME Passport.
ACCME INNOVATION PARTNER DISCLAIMER
Upon your acceptance in the evaluation and completion of this CME activity, Med Learning Group will share your completion information and certain personal details (e.g., name, National Provider Identifier, birthdate MM/DD) with the ACCME for inclusion in your CME Passport transcript and, as applicable, reporting to certifying, licensing, or other regulatory authorities you specify.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Speaker | Relationships | Manufacturer |
| Eric Kumar Singhi, MD | Advisory Board/Consultant | AstraZeneca, Novocure, Amgen, Janssen, Regeneron, BMS, Boehringer Ingelheim |
| Contracted research | Research funding from Rexanna’s Foundation for Lung Cancer | |
| Bruna Pellini, MD | Advisory Board/ Consultant | AstraZeneca, AbbVie, Bayer, Bristol Myers Squibb, Boehringer-Ingelheim, Catalyst, Caris, Gilead, Foundation Medicine, Johnson & Johnson, Lilly, Pfizer, Summit Therapeutics, Regeneron, Merus, Oncohost, and ThermoFisher |
| Research support paid to the institution | Merck, Bristol Myers Squibb, Orbit Genomics, and from the Bristol Myers Squibb Foundation/the Robert A. Winn Diversity in Clinical Trials Awards Program | |
| Contracted research | Merck, Bristol Myers Squibb, Orbit Genomics, and from the Bristol Myers Squibb Foundation/the Robert A. Winn Diversity in Clinical Trials Awards Program | |
| Speaker Honoraria | AstraZeneca, AMGEN, Bayer, Merck, Foundation Medicine, Gilead, Lilly, Regeneron, Oncohost |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Andrew Grzybowski, CEO of Med Learning Group, has nothing to disclose.
- Lauren Welch, COO of Med Learning Group, has nothing to disclose.
- Sharine Griggs, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Anita Misra-Press, Medical Director for Med Learning Group has nothing to disclose.
- Tom Bregartner, MBA, VP of Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Sarah Milano RN, MSN has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Russie Allen, M.M, Accreditation and Outcomes Manager for Med Learning Group, has nothing to disclose.
- Ben Masella, Program Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
Please listen to the podcast below:
RELEASED DATE: August 03, 2026
EXPIRATION DATE: August 03, 2027
Copyright © 2026 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
PROGRAM CHAIR/HOST
Eric Kumar Singhi, MD
Assistant Professor
The University of Texas MD Anderson Cancer Center
Houston, Texas
Podcast Guest Faculty
Bruna Pellini, MD
Chief of Thoracic Medical Oncology
Miami Cancer Institute
Baptist Health South Florida
Miami, Florida
OVERVIEW
This engaging Podcast Series explores different facets of integrating advances in identifying and treating HER2-mutant NSCLC. In the first of three podcasts, expert faculty discuss the distinct HER2 pathologic alterations identified in NSCLC patients including their prevalence and associated clinical characteristics. The second podcast examines the importance of comprehensive molecular profiling to improve outcomes in HER2-altered NSCLC including challenges faced in integrating diagnostic testing in the community setting. The final podcast in the series evaluates treatment sequencing strategies for advanced HER2-mutant NSCLC including new approvals for HER2-directed tyrosine kinase inhibitors as well as patient-specific factors that guide incorporation of these targeted treatments in first-line and beyond lines of therapy to improve efficacy and safety.
TARGET AUDIENCE
This activity is designed to meet the educational needs of community clinicians involved in the evaluation and management of patients with lung cancer including oncologists, nurses/nurse practitioners, and physician assistants.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Integrate molecular profiling into treatment pathways for NSCLC
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this virtual activity for a maximum of 0.25 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the virtual activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.25 ANCC contact hours.
ACCME INNOVATION PARTNER
Med Learning Group (MLG) is proud to be recognized as an ACCME Innovation Partner, leading the way in simplifying CME for physicians. As an Innovation Partner, MLG will be working with the ACCME by submitting credits directly to CME Passport.
ACCME INNOVATION PARTNER DISCLAIMER
Upon your acceptance in the evaluation and completion of this CME activity, Med Learning Group will share your completion information and certain personal details (e.g., name, National Provider Identifier, birthdate MM/DD) with the ACCME for inclusion in your CME Passport transcript and, as applicable, reporting to certifying, licensing, or other regulatory authorities you specify.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Speaker | Relationships | Manufacturer |
| Eric Kumar Singhi, MD | Advisory Board/Consultant | AstraZeneca, Novocure, Amgen, Janssen, Regeneron, BMS, Boehringer Ingelheim |
| Contracted research | Research funding from Rexanna’s Foundation for Lung Cancer | |
| Bruna Pellini, MD | Advisory Board/ Consultant | AstraZeneca, AbbVie, Bayer, Bristol Myers Squibb, Boehringer-Ingelheim, Catalyst, Caris, Gilead, Foundation Medicine, Johnson & Johnson, Lilly, Pfizer, Summit Therapeutics, Regeneron, Merus, Oncohost, and ThermoFisher |
| Research support paid to the institution | Merck, Bristol Myers Squibb, Orbit Genomics, and from the Bristol Myers Squibb Foundation/the Robert A. Winn Diversity in Clinical Trials Awards Program | |
| Contracted research | Merck, Bristol Myers Squibb, Orbit Genomics, and from the Bristol Myers Squibb Foundation/the Robert A. Winn Diversity in Clinical Trials Awards Program | |
| Speaker Honoraria | AstraZeneca, AMGEN, Bayer, Merck, Foundation Medicine, Gilead, Lilly, Regeneron, Oncohost |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Andrew Grzybowski, CEO of Med Learning Group, has nothing to disclose.
- Lauren Welch, COO of Med Learning Group, has nothing to disclose.
- Sharine Griggs, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Anita Misra-Press, Medical Director for Med Learning Group has nothing to disclose.
- Tom Bregartner, MBA, VP of Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Sarah Milano RN, MSN has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Russie Allen, M.M, Accreditation and Outcomes Manager for Med Learning Group, has nothing to disclose.
- Ben Masella, Program Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
Please listen to the podcast below:
RELEASED DATE: August 10, 2026
EXPIRATION DATE: August 10, 2027
Copyright © 2026 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
PROGRAM CHAIR/HOST
Eric Kumar Singhi, MD
Assistant Professor
The University of Texas MD Anderson Cancer Center
Houston, Texas
Podcast Guest Faculty
Bruna Pellini, MD
Chief of Thoracic Medical Oncology
Miami Cancer Institute
Baptist Health South Florida
Miami, Florida
OVERVIEW
This engaging Podcast Series explores different facets of integrating advances in identifying and treating HER2-mutant NSCLC. In the first of three podcasts, expert faculty discuss the distinct HER2 pathologic alterations identified in NSCLC patients including their prevalence and associated clinical characteristics. The second podcast examines the importance of comprehensive molecular profiling to improve outcomes in HER2-altered NSCLC including challenges faced in integrating diagnostic testing in the community setting. The final podcast in the series evaluates treatment sequencing strategies for advanced HER2-mutant NSCLC including new approvals for HER2-directed tyrosine kinase inhibitors as well as patient-specific factors that guide incorporation of these targeted treatments in first-line and beyond lines of therapy to improve efficacy and safety.
TARGET AUDIENCE
This activity is designed to meet the educational needs of community clinicians involved in the evaluation and management of patients with lung cancer including oncologists, nurses/nurse practitioners, and physician assistants.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Develop treatment strategies based on current evidence and patient-centered approaches to optimize management of HER2-mutant NSCLC
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this virtual activity for a maximum of 0.25 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the virtual activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.25 ANCC contact hours.
ACCME INNOVATION PARTNER
Med Learning Group (MLG) is proud to be recognized as an ACCME Innovation Partner, leading the way in simplifying CME for physicians. As an Innovation Partner, MLG will be working with the ACCME by submitting credits directly to CME Passport.
ACCME INNOVATION PARTNER DISCLAIMER
Upon your acceptance in the evaluation and completion of this CME activity, Med Learning Group will share your completion information and certain personal details (e.g., name, National Provider Identifier, birthdate MM/DD) with the ACCME for inclusion in your CME Passport transcript and, as applicable, reporting to certifying, licensing, or other regulatory authorities you specify.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Speaker | Relationships | Manufacturer |
| Eric Kumar Singhi, MD | Advisory Board/Consultant | AstraZeneca, Novocure, Amgen, Janssen, Regeneron, BMS, Boehringer Ingelheim |
| Contracted research | Research funding from Rexanna’s Foundation for Lung Cancer | |
| Bruna Pellini, MD | Advisory Board/ Consultant | AstraZeneca, AbbVie, Bayer, Bristol Myers Squibb, Boehringer-Ingelheim, Catalyst, Caris, Gilead, Foundation Medicine, Johnson & Johnson, Lilly, Pfizer, Summit Therapeutics, Regeneron, Merus, Oncohost, and ThermoFisher |
| Research support paid to the institution | Merck, Bristol Myers Squibb, Orbit Genomics, and from the Bristol Myers Squibb Foundation/the Robert A. Winn Diversity in Clinical Trials Awards Program | |
| Contracted research | Merck, Bristol Myers Squibb, Orbit Genomics, and from the Bristol Myers Squibb Foundation/the Robert A. Winn Diversity in Clinical Trials Awards Program | |
| Speaker Honoraria | AstraZeneca, AMGEN, Bayer, Merck, Foundation Medicine, Gilead, Lilly, Regeneron, Oncohost |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Andrew Grzybowski, CEO of Med Learning Group, has nothing to disclose.
- Lauren Welch, COO of Med Learning Group, has nothing to disclose.
- Sharine Griggs, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Anita Misra-Press, Medical Director for Med Learning Group has nothing to disclose.
- Tom Bregartner, MBA, VP of Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Sarah Milano RN, MSN has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Russie Allen, M.M, Accreditation and Outcomes Manager for Med Learning Group, has nothing to disclose.
- Ben Masella, Program Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
Please listen to the podcast below:
RELEASED DATE: August 19, 2026
EXPIRATION DATE: August 19, 2027
Copyright © 2026 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
